Methylenedioxymethamphetamine (MDMA, Ecstasy) Induced Changes in Drug Metabolism: Gender and Genetic Polymorphisms

This open-label trial (n=27) investigates how MDMA (105mg/70kg) is metabolised by the body and how differences in genes and sex (male/female) influence this.

Conducted by Parc de Salut Mar in collaboration with the National Institute on Drug Abuse (NIDA), the study assessed the role of CYP2D6, CYP3A4, CYP1A2, and catechol-O-methyltransferase (COMT) in MDMA metabolism, along with gender differences and the influence of genetic polymorphisms (CYP2D6, COMT, SERT) on MDMA’s pharmacokinetics and effects. Healthy male and female adults with prior MDMA use received a single MDMA dose (1.5 mg/kg; range 75-100 mg). The study measured MDMA and metabolite concentrations in plasma and urine, as well as physiological and subjective effects, to better understand individual variations in MDMA metabolism.

Topic Healthy Subjects
Compound MDMA
Country Spain
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

Parc de Salut Mar
This company doesn't have a full profile yet, it is linked to a clinical trial.

National Institute on Drug Abuse
This company doesn't have a full profile yet, it is linked to a clinical trial.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.